Iniciadas as atividades de educação médica continuada da UED-HAM / IFB, com o Curso de Revisão em Endocrinologia e Diabetes


Confira a programação do módulo de manutenção, o qual se desenvolverá entre os meses de Maio a Dezembro de 2014.

O CARE de final do ano, será realizado nos dias 21 e 22 de Novembro, com a presença do Prof Hossein Gharib, da Mayo Clinic, U.S.A., como convidado.HAM-IFB-Curso-2014

The Battle of Statin Guidelines discussed at UED-HAM scientific session



FDA approves albiglutide, a weekly GLP-1 receptor agonist for the treatment of type 2 DM


The FDA has approved albiglutide (Tanzeum), a once-weekly GLP-1 agonist for type 2 diabetes, the agency announced.

The drug is indicated for improving glycemic control along with diet and exercise, and can be used alone or in combination with existing diabetes drugs, FDA said in a press release.

The drug will, however, carry a risk evaluation and mitigation strategy (REMS) to inform healthcare providers about the “serious risks associated with Tanzeum,” according to the release.

It will also have a boxed warning on thyroid C-cell tumors (including medullary thyroid carcinoma) that have been observed in animal studies of some of the GLP-1 agonists, and drugmaker GlaxoSmithKline will have to conduct three postmarketing studies:

  • A case registry of at least 15 years’ duration to identify any increase in medullary thyroid cancer
  • A cardiovascular outcomes trial in patients with high baseline risk of cardiovascular disease, now being required for all type 2 diabetes drugs
  • A trial in pediatric patients

The “obesity paradox” wasn’t confirmed in a large prospective study from NEJM


Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes

Deirdre K. Tobias, Sc.D., An Pan, Ph.D., Chandra L. Jackson, Ph.D., Eilis J. O’Reilly, Sc.D., Eric L. Ding, Sc.D., Walter C. Willett, M.D., Dr.P.H., JoAnn E. Manson, M.D., Dr.P.H., and Frank B. Hu, M.D., Ph.D.

N Engl J Med 2014; 370:233-244January 16, 2014DOI: 10.1056/NEJMoa1304501



The relation between body weight and mortality among persons with type 2 diabetes remains unresolved, with some studies suggesting decreased mortality among overweight or obese persons as compared with normal-weight persons (an “obesity paradox”).


We studied participants with incident diabetes from the Nurses’ Health Study (8970 participants) and Health Professionals Follow-up Study (2457 participants) who were free of cardiovascular disease and cancer at the time of a diagnosis of diabetes. Body weight shortly before diagnosis and height were used to calculate the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters). Multivariable Cox models were used to estimate the hazard ratios and 95% confidence intervals for mortality across BMI categories.


There were 3083 deaths during a mean period of 15.8 years of follow-up. A J-shaped association was observed across BMI categories (18.5 to 22.4, 22.5 to 24.9 [reference], 25.0 to 27.4, 27.5 to 29.9, 30.0 to 34.9, and ≥35.0) for all-cause mortality (hazard ratio, 1.29 [95% confidence interval {CI}, 1.05 to 1.59]; 1.00; 1.12 [95% CI, 0.98 to 1.29]; 1.09 [95% CI, 0.94 to 1.26]; 1.24 [95% CI, 1.08 to 1.42]; and 1.33 [95% CI, 1.14 to 1.55], respectively). This relationship was linear among participants who had never smoked (hazard ratios across BMI categories: 1.12, 1.00, 1.16, 1.21, 1.36, and 1.56, respectively) but was nonlinear among participants who had ever smoked (hazard ratios across BMI categories: 1.32, 1.00, 1.09, 1.04, 1.14, and 1.21) (P=0.04 for interaction). A direct linear trend was observed among participants younger than 65 years of age at the time of a diabetes diagnosis but not among those 65 years of age or older at the time of diagnosis (P<0.001 for interaction).


We observed a J-shaped association between BMI and mortality among all participants and among those who had ever smoked and a direct linear relationship among those who had never smoked. We found no evidence of lower mortality among patients with diabetes who were overweight or obese at diagnosis, as compared with their normal-weight counterparts, or of an obesity paradox. (Funded by the National Institutes of Health and the American Diabetes Association.)

New book from UED-HAM available (novo livro da UED-HAM ja disponivel)


Confira aqui como adquiri-lo

Sucesso no Forum metabolico do HAM


Em breve todas as atividades estarao disponiveis!

First two long-term studies with incretin-based therapies showed no increases in the risk of pancreatitis


The results of SAVOR (saxagliptin) and EXAMINE (alogliptin) showed a positive pancreatic and CV safety profile, according to two publications in the New England Journal of Medicine.

Confira a programação do 5o Congresso Brasileiro de Densitometria, Osteoporose e Osteometabolismo


A programação já está completa e você pode programar-se para o final de outubro de 2013.

De 26- 30 de outubro, no Summerville Hotel em Muro Alto, Porto de Galinhas.BRADOO programa-27May2013

Testosterone replacement may benefits patients with type 2 diabetes


One study presented during the Annual Meeting of The American Association of Clinical Endocrinologists, in Phoenix, on T2DM male with low serum testosterone concentrations found that insulin resistance was reversed after testosterone replacement. They found a 25% increase in insulin sensitivity after 24 weeks of treatment compared with patients who received placebo.

Puberty interruption in transgender youth discussed on clinical session


This would lead to less harmful psycosocial consequences in the case that endocrinologist, therapist and the patient decide to change gender identity.

Go to Top